From GlobeNewswire: 2025-05-19 01:52:00

AB Science has received a Chinese patent protecting masitinib for the treatment of COVID-19 until 2041, adding to its long-term intellectual property protection. This patent covers methods of treating SARS-CoV-2 infection with masitinib, based on preclinical data showing its efficacy against the virus. AB Science also signed an exclusive licensing agreement with the University of Chicago for COVID-19 research. Positive results from a phase 2 study of masitinib in COVID-19 have been reported, confirming its anti-inflammatory and antiviral properties. The company specializes in protein kinase inhibitors and is listed on Euronext Paris.



Read more at GlobeNewswire: AB Science receives Chinese patent protecting masitinib in